Drug profile · INN
tridihexethyl chloride
PATHILON
tridihexethyl chloride (PATHILON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — tridihexethyl chloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tridihexethyl chloride (PATHILON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tridihexethyl chloride?
tridihexethyl chloride (PATHILON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tridihexethyl chloride?
PATHILON is a marketed brand name for tridihexethyl chloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tridihexethyl chloride?
tridihexethyl chloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.